imatinib mesylate has been researched along with Mast-Cell Leukemia in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Arock, M; Christen, D; Huber, M; Kaiser, A; Maschke-Neuß, K; Mohta, V; Mülfarth, R; Nitsche, M; Panse, J; Schmitz, S; Simons, I; Stuth, C; Toledo, MAS; Wilhelm, T; Zenke, M | 1 |
| Pardanani, A | 1 |
| Costello, PN; Krishnan, K; Manthri, S | 1 |
| Chang, CC; Dunn, P; Wang, RC; Ward, D | 1 |
| Chen, PM; Chiou, TJ; Gau, JP; Hong, YC; Hsiao, LT; Liu, CY; Liu, JH; Lu, DY; Tzeng, CH; Yu, YB | 1 |
| Hellmann, A; Lewandowski, K; Limon, J; Mital, A; Piskorz, A; Wasąg, B | 1 |
| Hirotab, S; Kitamura, Y | 1 |
| Aichberger, KJ; Böhm, A; Derdak, S; Fabbro, D; Gleixner, KV; Gruze, A; Manley, PW; Mayerhofer, M; Pickl, WF; Samorapoompichit, P; Sillaber, C; Sonneck, K; Valent, P | 1 |
| Kajiguchi, T; Lee, MJ; Lee, S; Neckers, L; Trepel, JB | 1 |
1 review(s) available for imatinib mesylate and Mast-Cell Leukemia
| Article | Year |
|---|---|
Kit as a human oncogenic tyrosine kinase.
Topics: Animals; Benzamides; Dimerization; Gastrointestinal Stromal Tumors; Homozygote; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Mice; Models, Biological; Mutation; Neoplasms; Neoplasms, Germ Cell and Embryonal; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Signal Transduction; Structure-Activity Relationship | 2004 |
8 other study(ies) available for imatinib mesylate and Mast-Cell Leukemia
| Article | Year |
|---|---|
Capitalizing on paradoxical activation of the mitogen-activated protein kinase pathway for treatment of Imatinib-resistant mast cell leukemia.
Topics: Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Mast Cells; Mitogen-Activated Protein Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit | 2023 |
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Topics: Adult; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Mast Cells; Mastocytosis, Systemic; Risk Assessment | 2023 |
Chronic mast cell leukaemia with exon 9
Topics: Antineoplastic Agents; Chronic Disease; Exons; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Treatment Outcome | 2020 |
Acute mast cell leukemia associated with t(4;5)(q21;q33).
Topics: Acute Disease; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 5; Cyclic GMP-Dependent Protein Kinase Type II; Gene Fusion; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Mast-Cell; Male; Middle Aged; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Time Factors; Translocation, Genetic; Treatment Outcome | 2017 |
Mast cell leukemia: an extremely rare disease.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Male; Piperazines; Pyrimidines; Staurosporine | 2014 |
A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; DNA Mutational Analysis; DNA, Neoplasm; Exons; Female; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Proto-Oncogenes; Pyrimidines; Treatment Outcome | 2011 |
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Topics: Anti-Bacterial Agents; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; CD2 Antigens; Cell Proliferation; Cells, Cultured; Cladribine; Down-Regulation; Doxycycline; Drug Evaluation, Preclinical; Drug Interactions; Drug Synergism; Female; Humans; Imatinib Mesylate; Immunophenotyping; In Vitro Techniques; Leukemia, Mast-Cell; Middle Aged; Mutation; Phosphorylation; Piperazines; Platelet Membrane Glycoproteins; Protein Kinase C; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tetraspanin 30 | 2006 |
KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia.
Topics: Active Transport, Cell Nucleus; Benzamides; beta Catenin; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Tyrosine | 2008 |